On March 17, 2026 Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, reported that it will present two posters and a minisymposium talk at the AACR (Free AACR Whitepaper) Annual Meeting 2026. These presentations display the breadth of Aarvik’s capabilities in the ADC space. The AACR (Free AACR Whitepaper) Annual Meeting will take place from April 17-22, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aarvik, along with collaborator ArriVent BioPharma, Inc. (Nasdaq: AVBP), will present a poster titled "AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers" (Poster Number 2660). AV-P138-ADC, also known as ARR-002, was discovered by Aarvik as part of a research collaboration with ArriVent, who subsequently exclusively licensed the molecule and plans global development. AV-P138-ADC (ARR-002) is a novel, site-specifically-conjugated, dual-target tetravalent ADC that may overcome the limitations of conventional single-target or bivalent bispecific ADCs to potentially provide a safer and more effective treatment option for a broad spectrum of ovarian and endometrial cancer patients.
Poster Details
Date and Time: Monday April 20, 2026 from 9 AM – 12 PM PT
Session Category, Title: Clinical Research, Targeted Antigen Therapies and Immunity
Location: Section 49, Board 12, Number 2660
Further illustrating the power of Aarvik’s proprietary MUTTA platform, the oral presentation titled "MUlti-epitope Targeting Tetravalent Antibody (MUTTA) platform for Developing NextGen ADCs with an Improved Therapeutic Window" (Abstract Presentation Number 6758) will demonstrate in vitro and in vivo validation of multi-target MUTTA ADCs and their improved therapeutic window compared to single-target ADCs, as well as the broad applicability of the MUTTA platform across several tumor antigens.
Minisymposium Details
Date and Time: Tuesday April 21, 2026 from 2:30 – 4:30 PM PT
Session Category, Title: Clinical Research, Targeted Therapy: Data Driven Approaches and Novel Drugs
Aarvik will also present a poster titled "Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic beta-Glucuronidase Cleavable Linker" (Poster Number 5757). This poster will demonstrate data on one of the novel linker-payloads engineered utilizing Aarvik’s proprietary AQUALINK platform that is designed to develop next generation ADCs with superior hydrophilic properties.
Poster Details
Date and Time: Tuesday April 21, 2026 from 2 – 5 PM PT
Session Category, Title: Experimental and Molecular Therapeutics, Multi-Axis Antineoplastic Agents
Location: Section 14, Board 15, Number 5757
"We are pleased to present data at AACR (Free AACR Whitepaper) 2026 resulting from Aarvik’s deep expertise in engineering proprietary multispecific antibodies, linkers and payloads through Aarvik’s MUTTA and AQUALINK platforms," said Jagath Reddy Junutula, PhD, Co-founder, President and CEO of Aarvik Therapeutics. "These presentations showcase the success that Aarvik continues to demonstrate as it relentlessly pursues novel therapies for hard-to-treat cancer indications through research and innovation."
"Aarvik continues to generate exciting data from the MUTTA and AQUALINK platforms," said Paul Polakis, PhD, Aarvik Fellow and Scientific Advisory Board member. "Aarvik’s approach, along with the other new approaches in the ADC field overall, can result in novel therapies for patients with cancer."
(Press release, Aarvik Therapeutics, MAR 17, 2026, View Source [SID1234663643])